Skip to main content
$0.39 -$0.01 (-2.5%)

02:15 PM EDT on 09/28/22

Nymox Pharmaceutical Corp (NASDAQ:NYMX)

CAPS Rating: 1 out of 5

A biopharmaceutical company with three proprietary products on the market and a R&D of drug & diagnostic products in development for the treatment of enlarged prostate, Alzheimer's disease contamination of food and drink products and bacterial infections.

Current Price $0.39 Mkt Cap $36.5M
Open $0.40 P/E Ratio 0.00
Prev. Close $0.40 Div. (Yield) $0.00 (0.0%)
Daily Range $0.38 - $0.40 Volume 14,400
52-Wk Range $0.19 - $2.15 Avg. Daily Vol. 123,241

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

64 Outperform
54 Underperform
 

All-Star Players

8 Outperform
23 Underperform
 

Wall Street

0 Outperform
0 Underperform
 

Top NASDAQ:NYMX Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

Bigsef77 (58.58)
Submitted October 03, 2018

Nymox Reports Safety Benefits of Fexapotide Treatments for Prostate Cancer and Benign Prostatic HyperplasiaGlobeNewswire•October 3, 2018HASBROUCK HEIGHTS, N.J., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NYMX) reported today… More

mjonesy1985 (97.79)
Submitted April 13, 2015

good entry point will be .99 - $1.01

Recent Community Commentary

Read the most recent pitches from players about NYMX.

Recs

0
Member Avatar OklaBoston (42.26) Submitted: 1/5/2020 5:03:31 PM : Outperform Start Price: $2.51 NASDAQ:NYMX Score: -99.18

Improving technicals as much as anything else.

Recs

1
Member Avatar Bigsef77 (58.58) Submitted: 10/3/2018 1:22:56 PM : Outperform Start Price: $1.47 NASDAQ:NYMX Score: -147.32

Nymox Reports Safety Benefits of Fexapotide Treatments for Prostate Cancer and Benign Prostatic Hyperplasia
GlobeNewswire•October 3, 2018

HASBROUCK HEIGHTS, N.J., Oct. 03, 2018 (GLOBE NEWSWIRE) -- Nymox Pharmaceutical Corporation (NYMX) reported today that after long-term safety assessments of repeated Fexapotide Triflutate (FT) intraprostatic injections, there have been no identifiable risks or serious side effects or adverse events identified associated or linked with the drug.

FT is Nymox's lead drug for which the Company is in the process of seeking U.S. and European marketing approvals for BPH (prostate enlargement), and FT is also in late stage development for prostate cancer. Pivotal trial results for FT BPH studies involving 977 treated patients were published in 2018 in the prestigious World Journal of Urology (May 2018, Volume 36, pages 801–809), and the safety and efficacy results have been presented to the American Urology Association and previously to the European Association of Urology.

Dr. Paul Averback, CEO of Nymox said, "For prostate cancer in particular, repeated injection treatments will be needed and a focal molecular treatment will have negligible value if there cannot be reliable safety expected from repeated injection. Prostate cancer is a multi-focal disease and it is to be expected that multiple focal molecular treatments will be utilized for optimal outcomes. Follow-up and re-treatment will be needed. Nymox undertook 2 large FT re-injection safety studies in 2010-2014 involving 351 subjects with BPH, who were subsequently followed for up to 7 years. These mandatory and adequately sized safety studies are absolutely required in order to demonstrate safety of re-injection, and this is a standard requirement."

Dr Averback added, "In addition, Nymox undertook extensive immunological testing involving over 1000 subject samples, demonstrating that FT does not lead to detectable antibody formation, which underlines FT safety and supports the lack of risk for allergic reactions. All laboratory testing and sexual function tests including semen analyses showed no changes in FT treated men compared to controls."

Nymox's lead drug Fexapotide (FT) has been in development for over 10 years and has been tested by expert clinical trial investigative teams in over 70 distinguished clinical trial centers throughout the US, and has been found after 7 years of prospective placebo controlled double blind studies of treatment of 977 U.S. men with prostate enlargement to not only show clinically meaningful and durable relief of BPH symptoms, but also to show a major reduction in the incidence of prostate cancer, compared to placebo and compared to the known and expected normal incidence of the disease. The same clinical program has also shown in a long-term blinded placebo group study an 82-95% reduction in the number of these patients who required surgery after they received FT in the trial, as compared to patients who did not receive FT but instead later received conventional approved BPH treatments (p<.0001).

Recs

0
Member Avatar superstar2 (99.45) Submitted: 9/13/2016 12:15:20 PM : Outperform Start Price: $3.69 NASDAQ:NYMX Score: -161.92

Impressive stage3 trial results on lead drug Fexapotide.

Leaderboard

Find the members with the highest scoring picks in NYMX.

Score Leader

BravoBevo

BravoBevo (99.97) Score: +397.02

God never does anything to cover a deficiency because He has none. Instead, everything that God does is to display His sufficiency, which is infinite. The chief end of God (and also should be of man) is to glorify God and to enjoy God forever.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
BetapegAnalytics < 20 8/18/2009 Underperform 5Y $4.51 -91.13% +276.33% +367.46 0 Comment
BicaChica 82.19 10/12/2009 Underperform 5Y $4.66 -91.42% +242.47% +333.88 0 Comment
roth450 25.16 7/23/2010 Underperform NS $3.80 -89.47% +237.83% +327.30 0 Comment
longtermgrowth09 31.52 12/17/2009 Underperform 5Y $4.27 -90.63% +233.31% +323.94 0 Comment
RUMBLINstrflame 67.19 12/2/2009 Underperform 5Y $4.52 -91.15% +231.63% +322.78 0 Comment
Okcfirefighter < 20 12/17/2010 Underperform 5Y $7.20 -94.45% +196.80% +291.25 0 Comment
boardwalken65 31.98 7/5/2011 Underperform 3M $8.24 -95.15% +175.86% +271.00 0 Comment
Theory1 < 20 6/3/2008 Underperform NS $3.93 -89.82% +177.65% +267.47 0 Comment
NetscribeHealthC 81.12 3/23/2007 Underperform 1Y $5.95 -93.28% +172.30% +265.58 1 Comment
flyboyl6 31.13 2/6/2007 Underperform NS $5.42 -92.62% +170.73% +263.35 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

There are no Wall Street tracker picks for NYMX.